HEXO reports over $16.2 million in total gross revenue in the second quarter of fiscal 2019
Total gross revenue for the quarter reached $16.2 million, an increase of 144% from the previous...
Read MoreSelect Page
Posted by Invest In Weed | Mar 14, 2019
Total gross revenue for the quarter reached $16.2 million, an increase of 144% from the previous...
Read MorePosted by Invest In Weed | Mar 12, 2019
CV Sciences, Inc. finished 2018 with strong sales momentum and enters 2019 well positioned to...
Read MorePosted by Invest In Weed | Mar 12, 2019
Cara Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing...
Read MorePosted by Invest In Weed | Mar 12, 2019
The Company is currently in the final stages of talks with a leading Ontario based...
Read MoreGet stock alerts, news & related alerts straight to your inbox!